Nutriband

Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. It delivers abuse deterrent fentanyl transdermal system which provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. It operates through the Pocono Coated Products and Active Intelligence segments. The company was founded by Gareth R. Sheridan and Serguei Melnik in 2012 and is headquartered in Orlando, FL.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. It operates through the Pocono Pharmaceuticals and 4P Therapeutics segments. The Pocono Pharmaceuticals segment relates to a coated products manufacturing entity. The 4P Therapeutics segment performs contract research and development services. The company was founded by Gareth R. Sheridan and Serguei Melnik in 2012 and is headquartered in Orlando, FL.

Nutriband Inc (NASDAQ: NTRB) is soaring Friday morning after the company announced the Korean Intellectual Property Office fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the company's lead technology AVERSA. AVERSA is 4p Therapeutics' abuse deterrent transdermal system, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches.

Why Nutriband Shares Are Soaring Today

ORLANDO, FL / ACCESSWIRE / December 31, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the Korean Intellectual Property Office (KIPO) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™. The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches.

Nutriband Inc. Issued Full Patent from the Korean Intellectual Property Office for Its "Abuse and Misuse Deterrent Transdermal System" Application

ORLANDO, FL / ACCESSWIRE / December 29, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of December 29, 2021, the Company had 7,773,962 shares of common stock outstanding.

Nutriband Inc. Announces $1 Million Share Repurchase Authorization

ORLANDO, FL / ACCESSWIRE / December 21, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced plans to start offering contract manufacturing services for liquid based topical, transdermal and cosmetic product's. This follows the recent certification as a cGMP facility following a full cGMP audit.

Nutriband Inc. Initiates Plans to Offer Topical Lotion Contract Manufacturing Services

ORLANDO, FL / ACCESSWIRE / December 13, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced that its manufacturing subsidiary Active Intelligence, has received cGMP certification following a full cGMP audit. The audit was conducted specifically in relation to the certification of Pharmaceutical OTC GMP, 21 CFR Part 211/210.

Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary

ORLANDO, FL / ACCESSWIRE / December 3, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced that its Chief Executive Officer Gareth Sheridan and President Serguei Melnik will be joined by members of the Company's board of directors and senior management to ring the NASDAQ Stock Market Opening Bell at 9:30 a.m. EST on Friday, December 3, 2021.

Nutriband Inc. to Ring NASDAQ Stock Market Opening Bell on December 3, 2021

ORLANDO, FL / ACCESSWIRE / November 16, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, has commenced the development of its lead product candidate, AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system. Following the Company's recent successful uplisting to NASDAQ and financing, the company has started the commercial development of AVERSA™ Fentanyl, which has the potential to be the world's first fentanyl transdermal system with abuse deterrent properties.

Nutriband Inc. Initiates Commercial Development of Lead Product AVERSA(TM) Fentanyl

Nutriband is advancing the development of transdermal products for currently injected compounds.

Nutriband: Advancing Transdermal Delivery Of Injectable Drugs

ORLANDO, FL / ACCESSWIRE / October 22, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, is pleased to announce the receipt of $2,062,500 in additional gross from the exercise of warrants issued in the Company's October 1, 2021 public offering of securities. Investors participating in Nutriband's financing exercised a total of 275,000 warrants at a price of $7.50 per share.

Nutriband Inc. Receives Additional $2,062,500 from Exercise of Warrants, Increasing Total Capital from Public Offering and Nasdaq Listing to Approx. $8.7M

ESS Tech

Inmode Ltd

Lithium Americas Corp

Ocugen, Inc.

Progenity

Quanterix

R.R. Donnelley & Sons

Tata Motors

Penny stocks are on the move Tuesday and we're taking a look at what's hot among traders of the volatile investments today. The post Hot Penny Stocks for Tuesday: Today's 10 Biggest Movers appeared first on InvestorPlace.

Hot Penny Stocks for Tuesday: Today's 10 Biggest Movers

The stock price of Nutriband Inc. (NASDAQ:NTRB) increased by over 35% during intraday trading today. This is why it happened.

NTRB Stock: Why It Substantially Increased Today

Nutriband (NTRB) stock is taking off on Tuesday thanks to news that it will be producing Covid-19 antibody check patches. The post NTRB Stock: 11 Things for Nutriband Investors to Know About the Covid-19 Antibody Indicator Patch appeared first on InvestorPlace.

NTRB Stock: 11 Things for Nutriband Investors to Know About the Covid-19 Antibody Indicator Patch

ORLANDO, FL / ACCESSWIRE / October 12, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products, today announced that it has signed an exclusive manufacturing agreement with San Diego-based Diomics for its Diocheck™ technology, a simple way for individuals to monitor for the presence of antibodies to SARS-CoV-2 (COVID-19) over an extended period of time. The goal of the Diocheck patch is to monitor the critical gap between when a person receives a COVID-19 vaccine and when a protective level of antibodies is circulating in the body, which current reports suggest could take several weeks.

Nutriband Inc. Signs Exclusive Manufacturing Agreement for Diocheck(TM) Visual COVID-19 Antibody Indicator Patch

JERSEY CITY, N.J., Oct. 6, 2021 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced the completion of an underwritten public offering of 1,056,000 units for Nutriband Inc. (NASDAQ: NTRB) at a public offering price of $6.25 per unit for total gross proceeds of $6.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses and before any exercise of the underwriters' overallotment option.

WallachBeth Capital Announces Completion of a $6.6 Million Underwritten Public Offering for Nutriband Inc. (NASDAQ: NTRB) and Up-listing to the NASDAQ Capital Market

LOS ANGELES--(BUSINESS WIRE)--Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products focused on preventing opioid abuse, announced that its common stock and warrants began trading on the Nasdaq Capital Market effective October 1, 2021. Nutriband also announced the pricing of an underwritten public offering of 1,056,000 units of securities at a public of

WestPark Capital Announces Completion of a $6.6 Million Public Offering for Nutriband Inc. (NASDAQ: NTRB) and Up-listing to the NASDAQ Capital Market

ORLANDO, FL / ACCESSWIRE / October 4, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products focused on preventing opioid abuse, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application 16/707,547, entitled 'Abuse and Misuse Deterrent Transdermal Systems'. The Patent, specifically relates to the company's AVERSA® technology focused on deterring the abuse and misuse of opioid based transdermal pain patches, specifically Fentanyl.

Nutriband Inc.'s AVERSA(R) technology receives Notice of Allowance from United States Patent and Trademark Office (USPTO)

ORLANDO, FL / ACCESSWIRE / October 1, 2021 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products focused on preventing opioid abuse, contract research and development services and the contract manufacturing of topical and transdermal products, today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market effective October 1, 2021. Nutriband also announced the pricing of an underwritten public offering of 1,056,000 units of securities at a public offering price of $6.25 per unit for total gross proceeds of $6.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market

Nutriband Inc. (NTRB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Nutriband Inc. (NTRB): Can Its 22% Jump Turn into More Strength?

Nutriband Inc. (NTRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Nutriband Inc. (NTRB) Soars 6%: Is Further Upside Left in the Stock?

News for Nutriband Stock (NTRB)